CSI Market
Sign In | Register

Syros Pharmaceuticals Inc (SYRS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SYRS Annual Cash Flow →
Reviewing cash flow figures over time highlights how Syros Pharmaceuticals Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2024)
9 Months 		(Jun 30 2024) (Mar 31 2024) (Dec 31 2023) (Sep 30 2023)
Operating Activities
Income-33.43
Depreciation & amortization0.99
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.13
Share-based Compensation5.53
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-51.66
Increase Decrease In Prepaid Expense And Other Current Assets-0.20
Increase Decrease In Contract With Customer Liability-
Increase Decrease In Operating Lease Asset And Liabilities-
Finance Lease Right Of Use Asset Amortization-
Operating Lease Expense-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-1.90
Increase (Decrease) in Accrued Liabilities-0.21
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.23
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.68
Discontinued operations0.00
Net Cash flow from Operating Activities-81.45
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities30.89
Payments to Acquire Marketable Securities-30.59
Real Estate Investments0.00
Proceeds From Disposition Of Asset Held For Sale0.13
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.43
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.12
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock And Warrants In Public Offerings And Private Placements Net Of Issuance Costs-
Proceeds From Issuance Of Convertible Preferred Stock And Warrants Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock Through Exercise Of Warrants-
Proceeds From Issuance Of Common Stock And Accompanying Warrants In Public Offerings And Private Placements Net Of Issuance Costs-
Proceeds From Issuance Of Convertible Preferred Stock And Accompanying Warrants In Public Offering Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock In Public Offering Net Of Issuance Costs-
Payment Of Issuance Cost Related To Out Of Period Offering And Debt Issuance-
Payments On Financing Lease Obligations-
Proceeds From Issuance Of Common Stock And Warrants In Public Offering Net Of Issuance Costs-
Payment Of Issuance Cost Related To Out Of Period Offering-
Payments On Financing And Capital Lease Obligations-
Payment To Creditor Related To Debt Modification-
Payment Of Issuance Cost Related To Underwritten Registered Direct Offering And At The Market Facility-0.34
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.22
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-81.45
Total Cash Flow-81.25
4 historic quarters locked

Sign in to unlock the full Syros Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Syros Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-119236

Figures are derived from filed reports and may be restated. Historical data is subject to revision.